Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients

Diabetes and Metabolism

Volumn 23, Issue 6, 1997, Pages 524-527

  Lunetta, M ^a   Mauro, M D I ^b   Moli, R L E ^c   Nicoletti, F ^d  

^a CANNIZZARO HOSPITAL   (Italy)

^b Endocrinology and Metabolic Diseases   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Counterregulatory hormones; Hypoglycaemia; Octreotide; Type 1 diabetes

Indexed keywords

ADRENALIN; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; MONOCOMPONENT INSULIN; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EPINEPHRINE; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE;

EID: 0031459359     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bauer W, Briner U, Doepfner W et al. SMS 201-995 : a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci, 1982, 31, 1133-1140.
2. Navascuez I, Gil J, Pascau C et al. Effect of a long-acting somatostatin derivative SMS 201-995 (Sandostatin) on glucose homeostasis in type I diabetes mellitus. Hormone Res, 1988 ; 29, 92-94.
3. Nosari I, Lepore G, Querci F et al. Effects of a somatostatin derivative (SMS 201-995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device. J Endocrinol Invest, 1989, 12, 413-417.
4. Plewe G, Nolken G, Krause U, Del Pozo E, Beyer J. Somatostalin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol, 1986, 21 (suppl.119), 166-169.
5. Grossmann LD, Shumak SL, George SR, et al. The effects of SMS 201-995 (Sandostatin) on metabolism profiles in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1989, 68, 63-67.
6. Spinas GA, Bock A, Keller U. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care, 1985, 8, 429-435.
7. Orskov H, Flyvbjerg A, Frystyl J, et al. Octreotide and diabetes : theoretical and experimental aspects. Metabolism, 1992, 41 (suppl. 2), 66-71.
8. Orskov L, Moller N, Bak JF, Porksen N, Schmitz O. Effects of somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism, 1996, 45, 211-217.
9. Navascues I, Gil J, Pascau C, Senen D, Serrano-Rios M. Severe hypoglycemia as a short-terra side-effect of the somatostatin analog SMS 201-995 in insulin-dependent diabetes mellitus. Horm Metab Res, 1988, 20, 749-750.
10. Scheen AJ, Gillet J, Rosenthaler J et al. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia, 1989, 32, 801-809.
11. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinologica (Copenh), 1989, 120, 187-194.
12. Report and recommendations of the San Antonio conference on. diabetic neuropathy. Diabetes, 1988, 37, 1000-1004.
13. De Feo P, Perriello G, Torlone E et al. Demonstration of a role for growth hormone in glucose conterregulation. Am J Physiol, 1989, 256, 835-843.
14. Bolli GB. From physiology of glucose counterregulauon to prevention of hypoglycaemia in type I diabetes mellitus. Diab Nutr Metab, 1990, 4, 333-349.
15. Cryer P, Gerich J. Glucose counterregulauon, hypoglycaemia, and intensive insulin therapy in diabetes mellitus. N EngI J Med, 1985, 313, 232-241.